The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1429
A Prostatic Urethral Lift for Benign Prostatic Hyperplasia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the use of a permanent prostatic urethral lift implant (UroLift – NeoTract) to relieve low or blocked urine flow in men ≥50 years old with benign prostatic hyperplasia (BPH).

TREATMENT OF BPH — Medical therapy is generally the first-line treatment for patients with moderate-to-severe lower urinary tract symptoms associated with BPH, but about 25% of patients discontinue medical therapy due to adverse effects.

Alpha1-blockers like tamsulosin (Flomax, and generics) can relax smooth muscle tone in the bladder neck, prostatic capsule, and prostatic urethra, relieving symptoms of urinary obstruction. They have no effect on the size of the prostate and can cause dizziness, orthostatic hypotension, syncope, and retrograde or diminished ejaculation.

5α-reductase inhibitors like dutasteride (Avodart) block conversion ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Prostatic Urethral Lift for Benign Prostatic Hyperplasia
Article code: 1429d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian